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Abstract: Growing data suggest oxidative
stress contributes to the pathogenesis of
Alzheimer’s disease (AD). The objective of this
study was to assess the value of antioxidant
potential (AOP), antioxidant status (AOS) and
thiobarbituric acid reactive substances
(TBARS) and the cysteine protease inhibitor
Cystatin C that plays a role in the processing
of amyloid _ as clinical markers of AD in
peripheral circulation and to find out the
agreement limits of AOP and AOS as clinical
laboratory tests. To do this, 21 severely
demented patients fitting the DSM-IV
diagnostic criteria for Alzheimer’s type
dementia as well as through minimental state
examination were compared to 20 agematching healthy controls with respect to
their serum AOP, AOS, Cystatin C and TBARS
levels. The under-curve area detected from
ROC curves for TBARS, AOS, AOP and
Cystatin C were 0.801, 0.622, 0.475 and
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Introduction
Oxidative stress refers to the cytopathologic
consequences of a mismatch between the production of
free radicals and the ability of a cell to defend against them
(1). Growing data from experimental models and human
brain studies suggest that oxidative stress may play an
important role in neuronal degeneration in diseases such as
Alzheimer’s disease (AD)(2). Mitochondrial oxidative
metabolism, nitric oxide, phospholipid metabolism and
proteolytic pathways are potential sources of intracellular
free radicals. Alterations in free radical defence systems
may also contribute to oxidative stress. A net increase in
reactive oxygen species can produce damage to lipids,
proteins and DNA, and induce necrosis or apoptosis.
One of the neuropathologic hallmarks of AD is the
deposition of extracellular aggregates of β-amyloid
peptides (Aβ). The finding that Aβ can be toxic to neurons
in vitro has led to the hypothesis that neuronal
degeneration in AD is due to Aβ toxicity (3). In vitro

0.65 respectively. Altman and Bland analysis
showed that the values obtained by the AOP
assay were 0.0149-0.04664 with a mean of
0.03081 units higher than those values
obtained via AOS assay, indicating a low level
of agreement. In addition, Pearson’s
correlation testing showed a significant
negative correlation between AOP and AOS
(r=0.479, p<0.01). As a conclusion, among
the tests investigated in this study, TBARS
may be used as a dependable peripheral
marker of AD with a sensitivity of 0.85 and a
specificity of 0.6 at the cut-off point of 0.77
nmol/ml. AOS should be preferred to AOP as
a marker with a specificity and sensitivity of
0.7 at the cut-off point of 0.011nmol/ml.
Further studies may be undertaken to reveal
the pathogenetic relation of oxidant stress and
the processing of amyloid β.
Key Words: Alzheimer’s disease, serum
oxidative stress marker, Cystatin C

evidence suggests that oxidative stress may contribute to
Aβ toxicity. Increases in H2O2 were detected in cells
following exposure to Aβ, and both vitamin E and catalase
prevented cell death (4,5). Cystatin C deposition in AD
has been reported as a secondary contributory event in
the pathogenesis of the disease rather than an
independent risk factor (6).
Oxidative stress may contribute to the aggregation of
soluble Ab into insoluble plaques. Soluble Aβ has been
found to aggregate in vitro by the addition of metal
catalyzed oxidation systems (7).
Levels of oxidative cellular damage are higher in the
brains of individuals with AD. Elevated products of lipid
peroxidation occur in vulnerable cortical regions in brains
with AD, and neurofibrillary tangle bearing neurons have
enhanced immunoreactivity for malondialdehyde (MDA),
the biochemical marker of lipid peroxidation (8). To date,
it is not clear if this free radical generation is secondary
to other initiating causes, though they are deleterious and
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form a part of the cascade of events that can lead to
neuron death suggesting that therapeutic efforts aimed at
the removal of reactive oxygen species (ROS) or the
prevention of their formation may be beneficial in AD.
The level of systematic oxidant stress has been
questioned by several investigators in the literature (912) and different results have been reported. It has also
been suggested that a decrease in blood brain barrier
function is possible in dementia disorders (13). Cystatin C
has been found to be enriched in the cerebrospinal fluid
(CSF) of patients with AD and a decrease in blood brain
barrier function in dementia disorders has been
suggested as a possibility (14). In the light of these
findings, we hypothesized that serum levels of Cystatin C
may vary in relation to AD detected clinically.
The parameters of antioxidant potential (AOP) and
antioxidant status (AOS) are used to assess antioxidants,
but they do not give any information about the enzymatic
and non-enzymatic constituents of the total balance.
Circulatory thiobarbituric acid reactive substances
(TBARS) give information on the level of lipid
peroxidation that is the product of oxidative stress which
could not be counterbalanced by antioxidants originating
from other tissue in the body.
In this study, we aimed to test if AOP, AOS and
TBARS determination in the systemic circulation of
patients with AD could be used as a clinical index for
diagnosis as well as comparing the statistical agreement
of AOP and AOS assays.
Materials and Methods
Twenty one severely demented patients with a mean
age of 81 (min: 71, max: 96) comprising 15 females and
6 males with a mean Mini Mental State Examination
(MMSE) score of 9/30 (min: 3, max: 12) were included
in the study, most of whom had been referred to the
geropsychiatry unit due to their behavioural disturbances.
Dementia diagnoses were applied through interviews
with caregivers and other informants such as social
workers and psychologists. The diagnosis of dementia
was strengthened by applying DSM IV diagnostic criteria
for dementia of Alzheimer’s type and giving the patients
an MMSE (15). Types of dementia other than AD were
excluded by the presence of cerebrovascular accident
history and stepwise deterioration.
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Cranial Computerized Tomographies (CT) were
performed primarily to rule out silent infarcts and to
detect cortical atrophy and ventricular enlargement.
Other causes of dementia such as Pick’s disease were
excluded by the presence of frontotemporal atrophy and
early cognitive impairment in the conservation of
personality at an early stage. Dementia of Huntington’s
disease and Parkinson’s disease types were excluded by
the presence of motor abnormalities. Other types of
dementia were excluded via medical history, such as the
presence of alcohol use, other metabolic and infectious
disorders or a history of head injury.
Consent was obtained, and the study was conducted
in accordance with the Helsinki Declaration. Blood was
obtained in accordance with NCCLS recommendations.
Sera was seperated from whole blood and stored at
–80ºC until the assays were performed. Blood from 20
healthy age matching controls was simultaneously
collected.
Biochemical Assays
Antioxidant defence potential was assessed as
described previously (16). In brief, the reaction medium
enriched with fish oil samples were exposed to
superoxide radical produced by the xanthine/xanthine
oxidase system for one hour and then malondialdehyde
levels were measured as previously described. By using
this reaction system, it is suggested that it is possible to
obtain more precise information on the antioxidant
potentials of the samples. The antioxidant potential value
was assessed from the differences between MDA levels in
blanks and samples, which was proportional to the AOP
values of the samples. Results were expressed as nmol
ml-1h-1. The analysis scheme is given in Table 1.
Total antioxidant status was assessed by the kit from
Randox (Randox Laboratories Ltd., Antrim, UK) on a
Technicon RA-XT autoanalyzer (Bayer, Germany). The
assay principle depends on the incubation of 2,2’ –Azinodi-(3-ethylbenzthiazoline sulphonate) (ABTS) with
peroxidase (metmyoglobin) and H2O2 to produce the
radical cation ABTS*+. This has a relatively stable blue
colour, which is measured at 600 nm. Antioxidants in the
added sample cause the suppression of this colour
production to a degree which is proportional to their
concentration (17).
TBARS was measured as described previously (18).
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Table 1.

Analysis scheme of the antioxidant defense potential (AOP)
measurement.

Sample
Fish Oil*
Xanthine (10mM)
Xanthine Oxidase**

Sample

Sample (ml)

Blank (ml)

0.2
0.01
0.1
0.1
Incubation for 1 hr at room
temperature (25oC)
MDA measurement

0.01
0.1
0.1

Finally, the agreement between AOP and AOS was
determined by the Blant and Altman method (20).
Student’s t-test was applied to test the difference
between the means. Furthermore, a ROC curve was
generated to suggest a best cut-off point to discern
patients with Alzheimer’s disease from age matching
controls considering the Cystatin C levels with best
sensitivity and specificity.

0.2

*

Prepared by dissolving 1 ml fish oil (with total lipid content of
0.706 g/ml) in 2 ml acetone
** Prepared by diluting Xanthine Oxidase (XO) (Sigma X-4500, 2.9
mg protein/ml, 1.6 U/mg protein) 40-fold in (NH4)2SO4 solution of
2M. Final amount of XO in the assay medium was 0.012U

Cystatin C is a serum protein that is known to be
elevated in patients with deteriorated kidney functions
(19). To rule out the presence of kidney function
deterioration, and the dependent increase in serum
Cystatin C levels, serum creatinine assays were done to
each patient prior to inclusion in the study group. Two
patients and 1 control were excluded from the study due
to high serum creatinine levels. Serum creatinine assays
were done by the Jaffe method (Beckman reagent, CA)
on a CX7 autoanalyzer (Beckman, CA). The red colour
complex formed on mixing samples with alkaline picrate
reagent is monitored bichromatically by detectors at 520
and 560 nm. The observed rate of complex formation is
directly proportional to the concentration of creatinine in
the sample. Serum Cystatin C assay, were made by the
latex particle enhanced turbidimetric (pet) immunoassay
(DAKO, CA) on the CX7 analyzer (Beckman, CA). The
DAKO Cystatin C pet kit contains polystyrene particles of
uniform size, chemically coupled with rabbit antibody
against human Cystatin C. A reaction between these
immunoparticles and Cystatin C in a patient’s specimen
results in the formation of agglutinates and a
concomittant change in the absorbance signal. The
Cystatin C concentration of the patient’s specimen is
determined by interpolation on a calibration curve.
Statistics
Differences between the means was calculated by
Student’s t-test. ROC curves and Pearson’s correlation
analysis were assessed using SPSS 9.0 for Windows.

Results
The comparison of the means and standard deviations
of serum antioxidant potential, total antioxidant status
and TBARS are shown in Figure 1 a-c. Accordingly, serum
TBARS levels of AD patients were significantly higher
than the controls (p<0.01). To test the value of TBARS
as well as AOS and AOP as clinical laboratory markers of
AD, we outlined the ROC curves in Figure 2. The
demonstrated area under the curves, cut-off points, the
sensitivity and the specificity of TBARS, AOP and AOS
tests to detect AD are shown in Table 2. This study also
demonstrated that there is a significant negative
correlation between serum antioxidant potential and
serum total antioxidant (Figure 3a). The agreement limits
calculated by the Altman and Bland test is shown in Figure
3b. Accordingly, the agreement limits are between
–0.04664 and –0.01497 with a mean of –0.03081
units. Thus, AOS gives better results than AOP at all
times.
The means and standard deviations for both creatinine
and Cystatin C are given in Table 3. The reference range
suggested for Cystatin C for patients older than 50 years
is 0.74-1.55 mg/L, whereas the reference range for
creatinine was 0.6-1.3 mg/L. Accordingly, the difference
between the means of the control group and the AD
group was insignificant (p=0.58) for creatinine levels.
This finding confirms that any change in the Cystatin C
levels of the AD group would not be due to kidney
dysfunction. However, there was a difference between
the means of the AD group and the control group for
serum Cystatin C levels (p=0.05). As shown in Figure 4,
the area under the ROC curve for Cystatin C for AD
patient determination was 65%. The sensitivity and 1Specificity values for suggested cut-off points are shown
in Table 4. Accordingly, with a cut off-point of 1.275
mg/L, AD was differentiated by Cystatin C levels with a
sensitivity of 0.526 and a specificity of 0.895.
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0.0112 —
0.0108 —

0.02 —
0.01 —

0.0104 —

0

0.01
Patient

Patient

Control

Control

Table 2.

The Cut-off Values, Sencitivity, Spesificity and Area Under
the ROC Curve for TBARS, AOP and AOS in Alzheimer’s
Disease.

0.7705 nmol/ml
0.0443 nmol/ml
0.0115 nmol/ml

0.857
0.524
0.700

Spesificity

Area Under
the Curve

0.600
0.500
0.700

0.801
0.475
0.622

—

0.6

—

0.4

—

0.2

—

0

Comparison of Creatinine and cystatin-C Levels in AD
Patients versus Controls.

Figure 2.
Mean±Standard Deviation

p

CREATININE (mg/dl) AD
Control

0.810 ± 0.323
0.858 ± 0.186

0.58

CYSTATIN-C (mg/L)

1.227 ± 0.521
0.958 ± 0.279

0.05

AD
Control

—

1

—

0.8

—

0.6

—

0.4

—

0.2

—

Patient

Control

AOS
AOP
TBARS

0
Table 3.

1.2

c
*

—

TBARS
AOP
AOS

Sensitivity

0.8

—

—

Cut-off

Sensitivity

Circulatory levels of a. AOP, b. AOS and c. TBARS in Alzheimer’s patients and control groups.

—

1.4

0

Figure 1.

1

—

0.2

0.4
0.6
1-Specificity

—

0.03 —

0.0116 —

TBARS (nmol/ml)

AOP (nmol/ml)

AOP (nmol/ml)

0.04 —

—

1.6

—

0.012

0.05 —

b

—

0.0124 —

a

0.06 —

0.8

1

ROC curve for detection of sensitivity and specificity in tests
of AOS, AOP and TBARS in Alzheimer’s patients detected
clinically as described in the text.

.06 —
.05 —

0.05 —

.02 —

Diff (AOS-AOP)

.03 —

0.04 —
0.03 —

.01 —
.00 —
-.01 —
-.02 —

0.02 —
0.01 —
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-.04 —

0.011

0.0115
0.012
AOS (nmol/ml)

Correlation analysis between AOP and AOS.

0.0125

—

—

—

—

—

—

—

—

—

—

—

—

-.05 —

0
0.0105

Figure 3a.

-.03 —

r = 0.479
p<0.01
—

AOP (nmol/ml)

.04 —
0.06 —

-.06
.018 .020 .022 .024 .026 .028 .030 .032 .034 .036
Average (AOS+AOP)/2
Figure 3b.

Differences against mean for antioxidant status (potential).
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1.00 —

Table 4.

Cut-off value (mg/L)

Diff (AOS-AOP)

.75 —

.50 —

—

.50
1 - Specificity

—

.25

—

0.00
0.00

—

.25 —

Figure 4.

Sensitivity and Specificities Attained with Suggested Cut-off
Values for Cystatin-C.

.75

1.00

Sensitivity

Specificity

0.520

0.895

0.053

0.745

0.789

0.263

0.950

0.579

0.474

1.275

0.526

0.895

1.540

0.316

1

2.180

0.053

1

3.330

0

1

ROC curve for Cystatin C.

Discussion
Several investigators have determined the presence of
increased lipid peroxidation products in the brain
homogenates of patients with AD (21,22). However, to
our knowledge, there are no studies investigating the
value of serum AOS, AOP and TBARS as a laboratory test
to diagnose AD. This study demonstrated that the
peripheral levels of TBARS is a good indicator to
differentiate AD. However, it should be noted that the
patients included in this study were all severely demented.
It has been suggested that at severe stages of dementia
there may be a dysfunction of the blood-brain barrier
(BBB), and the apparent increase in serum TBARS levels
may be attributed to increased membrane peroxidation in
the central nervous system detected peripherally due to a
loss of BBB. With a cut off-point of 1.275 mg/L, AD could
be differentiated by Cystatin C levels with a sensitivity of
0.526 and a specificity of 0.895. It is possible to plan
larger studies to compare the Cystatin C test with other
biochemical markers like Apo E, CSF tau (23),
neuropeptides (24), diagnostic investigations like MRI,
SPECT, PET, fMRI and MRS (25) and psychological tests
like MMSE. With these results, we believe it is worthwhile
to undertake further research that might include
correlations of serum Cystatin C levels with CSF levels in
early and late stages of dementia of an AD type supported
by post-mortem immunopathology to decipher the
mechanism of appearance of Cystatin C in peripheral
circulation. Studies to be planned on larger groups will be
informative either to support the cut-off points suggested
in this study or to attain a better clinical utilization of
Cystatin C to detect AD.

The other parameters tested as candidates for
peripheral AD markers were AOS and AOP neither of
which displayed a difference in means when compared to
the control group. Previously, Sinclair et al. (26) have
also investigated the difference in total antioxidant
capacity (TAC) in the plasma of patients with AD and
normal controls. Even though there was no difference in
TAC, they observed lower vitamin E levels but similar
vitamin C and β-carotene levels in AD patients when
compared to controls. Riviera et al. (27), on the other
hand, demonstrated decreased vitamin C and stable
vitamin E levels in AD patients. The peripheral enzymatic
antioxidant defence system is a manifestation of tissue
degradation as these enzymes are intracellular. Thus,
the AOP or AOS activity consists mostly of nonenzymatic anti-oxidant defense systems. Even though
our study was also unable to prove any significant
change in AOP or AOS, we believe it is worthwhile to
further investigate the constituents of AOP or AOS to be
able to suggest dietary interventions for the prevention
of AD. The ROC curves showed that AOP and AOS are
not as good indicators as TBARS for the differentiation
of AD. In other words, these results imply that the
systemic levels of antioxidants is not a dependable
marker to reflect the buffering activity of neural
antioxidant stress.
This study also provided evidence that, from a
laboratory science point of view AOP and AOS tests have
a low level of agreement. AOP is always higher than AOS,
and they have significant negative correlation. This can be
explained by the fact that these two assays are measuring
chemically different substances, even though they were
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both suggested to be measuring the total antioxidant
capacity in the sample.
Studies to follow may target the utility of TBARS as a
differentiator of AD from other etiologies of dementia as
well as linking the severity of memory loss with TBARS
levels in circulation. The response of AD patients at
different stages to different therapeutic modalities may
further illuminate the pathophysiologic cascades involving
lipid peroxide generation.
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